Thermo Fisher Scientific Inc (TMO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $259.44B
Last updated: Nov 17, 2026 at 11:06 AM ET
Thermo Fisher Scientific Inc (TMO) Earnings: Report Dates and Results
Thermo Fisher Scientific (TMO) is expected to report earnings on Jan 27, 2027. In the quarter ended Sep 30, 2026, Thermo Fisher Scientific reported EPS of $6.68, above the $6.40 estimate. It beat the EPS estimate in each of the last 13 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TMO has an expected report date of Jan 27, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 9.4% above the $6.57 reported for the quarter ended Dec 31, 2025.
TMO Earnings Call
The latest TMO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, TMO beat 38, missed 1 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $12.14B, up 9.2% from $11.12B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $6.68 | $6.40 | $6.33 - $6.47 | +4.38% | Beat | +15.4% | 22 | 2 up, 1 down | Oct 21, 2026 | $12.14B |
| Jun 30, 2026 | $6.03 | $5.71 | $5.65 - $5.75 | +5.60% | Beat | +12.5% | 21 | 2 up, 12 down | Jul 23, 2026 | $11.99B |
| Mar 31, 2026 | $5.44 | $5.24 | $5.02 - $5.34 | +3.82% | Beat | +5.6% | 19 | 4 up, 6 down | Apr 23, 2026 | $11.01B |
| Dec 31, 2025 | $6.57 | $6.45 | $6.38 - $6.51 | +1.86% | Beat | +7.7% | 21 | 1 up, 1 down | Jan 29, 2026 | $12.21B |
| Sep 30, 2025 | $5.79 | $5.50 | $5.44 - $5.64 | +5.27% | Beat | +9.7% | 20 | 3 up, 3 down | Oct 22, 2025 | $11.12B |
| Jun 30, 2025 | $5.36 | $5.23 | $5.19 - $5.29 | +2.49% | Beat | -0.2% | 21 | 3 up, 3 down | Jul 23, 2025 | $10.86B |
| Mar 31, 2025 | $5.15 | $5.10 | $5.02 - $5.14 | +0.98% | Beat | +0.8% | 22 | 2 up, 7 down | Apr 23, 2025 | $10.36B |
| Dec 31, 2024 | $6.10 | $5.94 | $5.72 - $6.00 | +2.69% | Beat | +7.6% | 21 | 2 up, 2 down | Jan 30, 2025 | $11.39B |
| Sep 30, 2024 | $5.28 | $5.25 | $5.15 - $5.43 | +0.57% | Beat | -7.2% | 23 | 1 up, 2 down | Oct 23, 2024 | $10.60B |
| Jun 30, 2024 | $5.37 | $5.12 | $5.05 - $5.20 | +4.88% | Beat | +4.3% | 20 | 4 up, 1 down | Jul 24, 2024 | $10.54B |
| Mar 31, 2024 | $5.11 | $4.71 | $4.61 - $4.75 | +8.49% | Beat | +1.6% | 20 | 3 up, 1 down | Apr 24, 2024 | $10.35B |
| Dec 31, 2023 | $5.67 | $5.64 | $5.62 - $5.73 | +0.53% | Beat | +5.0% | 20 | 1 up, 0 down | Jan 31, 2024 | $10.89B |
| Sep 30, 2023 | $5.69 | $5.61 | $5.45 - $5.78 | +1.43% | Beat | +12.0% | 21 | 1 up, 1 down | Oct 25, 2023 | $10.57B |
| Jun 30, 2023 | $5.15 | $5.43 | $5.25 - $5.57 | -5.16% | Miss | -6.5% | 22 | 2 up, 0 down | Jul 26, 2023 | $10.69B |
| Mar 31, 2023 | $5.03 | $5.03 | $4.78 - $5.28 | 0.00% | In line | -30.6% | 22 | 2 up, 1 down | Apr 26, 2023 | $10.71B |
| Dec 31, 2022 | $5.40 | $5.20 | $5.06 - $5.32 | +3.85% | Beat | -17.4% | 21 | 1 up, 1 down | Feb 1, 2023 | $11.45B |
| Sep 30, 2022 | $5.08 | $4.82 | $4.56 - $5.12 | +5.39% | Beat | -11.8% | 20 | 4 up, 1 down | Oct 26, 2022 | $10.68B |
| Jun 30, 2022 | $5.51 | $4.98 | $4.72 - $5.42 | +10.64% | Beat | -1.6% | 19 | 2 up, 1 down | Jul 28, 2022 | $10.97B |
| Mar 31, 2022 | $7.25 | $6.21 | $5.42 - $6.87 | +16.75% | Beat | +0.6% | 19 | 2 up, 1 down | Apr 28, 2022 | $11.82B |
| Dec 31, 2021 | $6.54 | $5.27 | $4.78 - $7.09 | +24.10% | Beat | -7.8% | 19 | 5 up, 0 down | Feb 2, 2022 | $10.70B |
| Sep 30, 2021 | $5.76 | $4.70 | $4.45 - $5.10 | +22.55% | Beat | +2.3% | 18 | N/A | Oct 27, 2021 | $9.33B |
| Jun 30, 2021 | $5.60 | $5.47 | $4.74 - $5.90 | +2.38% | Beat | +44.0% | 19 | N/A | Jul 28, 2021 | $9.27B |
| Mar 31, 2021 | $7.21 | $6.68 | $6.08 - $7.58 | +7.93% | Beat | +145.2% | 19 | N/A | Apr 29, 2021 | $9.91B |
| Dec 31, 2020 | $7.09 | $6.57 | $5.79 - $7.43 | +7.91% | Beat | +99.7% | 19 | N/A | Feb 1, 2021 | $10.55B |
| Sep 30, 2020 | $5.63 | $4.30 | $3.45 - $4.85 | +30.93% | Beat | +91.5% | 17 | N/A | Oct 21, 2020 | $8.52B |
| Jun 30, 2020 | $3.89 | $2.89 | $1.89 - $3.50 | +34.60% | Beat | +28.0% | 16 | N/A | Jul 22, 2020 | $6.92B |
| Mar 31, 2020 | $2.94 | $2.82 | $1.97 - $2.99 | +4.26% | Beat | +4.6% | 15 | N/A | Apr 22, 2020 | $6.23B |
| Dec 31, 2019 | $3.55 | $3.54 | $3.51 - $3.60 | +0.28% | Beat | +9.2% | 17 | N/A | Jan 30, 2020 | $6.83B |
| Sep 30, 2019 | $2.94 | $2.89 | $2.83 - $3.00 | +1.73% | Beat | +12.2% | 13 | N/A | Oct 23, 2019 | $6.27B |
| Jun 30, 2019 | $3.04 | $3.00 | $2.94 - $3.06 | +1.33% | Beat | +10.5% | 15 | N/A | Jul 24, 2019 | $6.32B |
| Mar 31, 2019 | $2.81 | $2.74 | $2.68 - $2.76 | +2.55% | Beat | +12.4% | 15 | N/A | Apr 24, 2019 | $6.13B |
| Dec 31, 2018 | $3.25 | $3.18 | $3.16 - $3.24 | +2.20% | Beat | +16.5% | 16 | N/A | Jan 30, 2019 | $6.51B |
| Sep 30, 2018 | $2.62 | $2.56 | $2.48 - $2.60 | +2.34% | Beat | +13.4% | 15 | N/A | Oct 24, 2018 | $5.92B |
| Jun 30, 2018 | $2.75 | $2.63 | $2.60 - $2.66 | +4.56% | Beat | +19.6% | 14 | N/A | Jul 25, 2018 | $6.08B |
| Mar 31, 2018 | $2.50 | $2.41 | $2.30 - $2.61 | +3.73% | Beat | +20.2% | 14 | N/A | Apr 25, 2018 | $5.85B |
| Dec 31, 2017 | $2.79 | $2.67 | $2.64 - $2.75 | +4.49% | Beat | +15.8% | 14 | N/A | Jan 31, 2018 | $6.05B |
| Sep 30, 2017 | $2.31 | $2.25 | $2.18 - $2.30 | +2.67% | Beat | +13.8% | 12 | N/A | Oct 25, 2017 | $5.12B |
| Jun 30, 2017 | $2.30 | $2.27 | $2.22 - $2.32 | +1.32% | Beat | +13.3% | 14 | N/A | Jul 26, 2017 | $4.99B |
| Mar 31, 2017 | $2.08 | $2.02 | N/A | +2.97% | Beat | +15.6% | N/A | N/A | Apr 26, 2017 | $4.76B |
| Dec 31, 2016 | $2.41 | $2.38 | N/A | +1.26% | Beat | +13.7% | N/A | N/A | Jan 31, 2017 | $4.95B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $22.87, up 4.6% from the year before. It was $8.27 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $22.87 | +4.6% |
| Dec 31, 2024 | $21.86 | +1.5% |
| Dec 31, 2023 | $21.54 | -7.3% |
| Dec 31, 2022 | $23.24 | -7.4% |
| Dec 31, 2021 | $25.11 | +28.4% |
| Dec 31, 2020 | $19.55 | +58.4% |
| Dec 31, 2019 | $12.34 | +11.0% |
| Dec 31, 2018 | $11.12 | +17.3% |
| Dec 31, 2017 | $9.48 | +14.6% |
| Dec 31, 2016 | $8.27 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,250 | 11 | |
| 2026Q2 | Jun 30, 2026 | 7,693 | 12 | |
| 2026Q1 | Mar 31, 2026 | 6,476 | 12 | |
| 2025Q4 | Dec 31, 2025 | 8,827 | 10 | |
| 2025Q3 | Sep 30, 2025 | 8,844 | 11 | |
| 2025Q2 | Jun 30, 2025 | 8,505 | 10 | |
| 2025Q1 | Mar 31, 2025 | 8,126 | 10 | |
| 2024Q4 | Dec 31, 2024 | 7,728 | 10 |
2026Q3 Earnings Call
Opening remarks
Rafael Tejada Vice President, Investor Relations Good morning, and thank you for joining us. On the call with me today is Marc Casper, our Chairman and Chief Executive Officer, and Jim Meyer, Senior Vice President and Chief Financial Officer. Please note this call is being webcast live and will be archived on the investors section of our website, thermofisher.com, under the heading News, Events and Presentations, until the next quarterly earnings call. A copy of the press release of our third quarter earnings is available in the investors section of our website under the heading Financials. Before we begin, let me briefly cover our safe harbor statement. Various remarks that we may make about the company's future expectations, plans and prospects constitute forward-looking statements within the meaning of applicable securities laws. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties, including those discussed in the company's most recent reports on Form 10-K and Form 10-Q under the heading Risk Factors. These forward-looking statements are based on our current expectations and speak only as of the date they are made. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even in the event of new information, future developments, or otherwise. Also, during this call, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is available in the press release of our third quarter earnings, and also in the investors section of our website under the heading Financials. With that, I'll now turn the call over to Marc.
Marc Casper Chairman and Chief Executive Officer Thank you, Raf. Good morning, everyone, and thanks for joining us today for our third quarter call. As you saw in our press release, we delivered another excellent quarter with outstanding financial performance. We are advancing our proven growth strategy and continuing to strengthen our trusted partner status with customers. Our PPI Business System is enabling outstanding execution across the company. Looking ahead, we are incredibly well-positioned to deliver an excellent 2026 as we continue to drive long-term value creation for all of our stakeholders and build an even brighter future for our company. To start, let me recap the third quarter financial results. Our revenue grew 9% to $12.14 billion. Adjusted operating income grew 15% to $2.97 billion. Adjusted operating margin expanded by 120 basis points to 24.5%. We grew adjusted EPS by 15% to $6.68 per share. Turning to our performance by end market, let me provide some details on how the quarter played out.
Frequently Asked Questions About TMO
When is Thermo Fisher Scientific's next earnings date?
Thermo Fisher Scientific's next earnings report is expected for Jan 27, 2027.
Did TMO beat earnings estimates last quarter?
Yes. Thermo Fisher Scientific reported EPS of $6.68 for the quarter ended Sep 30, 2026, above the $6.40 estimate, a 4.38% surprise.
What EPS do analysts expect from TMO next quarter?
The consensus EPS estimate for Thermo Fisher Scientific for the quarter ending Dec 31, 2026 is $7.19 from 23 analysts, with estimates from $6.86 to $7.62.
How often does TMO beat earnings estimates?
Thermo Fisher Scientific beat the EPS estimate in each of the last 13 quarters, with an average surprise of +3.31%.
TMO pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts